New triple therapy aims to save voice boxes in head and neck cancer patients
NCT ID NCT07310771
First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tests a combination of three drugs (sintilimab, nimotuzumab, and chemotherapy) followed by radiation with nimotuzumab in 23 adults with advanced head and neck cancer. The main goal is to see if this approach can help preserve the larynx (voice box) three months after treatment. Participants must have a type of cancer that tests positive for EGFR and have not had prior treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA-SCCHN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.